Researchers at UC San Diego, San Diego State University, and international collaborators have designed and validated a prediction model to signal counties at risk of future overdose death outbreaks.
June 2021 AJPH Issue highlights COVID-19 concerns in relation to fatal drug overdoses, drops in youth e-cigarette use, importance of public health measures, and strategies to protect correctional staff.
The Foundation for Opioid Response Efforts (FORE) and the Addiction Policy Forum (APF) are launching a program to assist people with substance use disorder obtain COVID-19 vaccinations.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.
Cocaine continues to be one of the most commonly abused illicit drugs in the United States. Pre-clinical literature suggests that targeting glucagon-like peptide-1 receptors (GLP-1Rs) in the brain may represent a novel approach to treating cocaine use disorder. Specifically, GLP-1R agonists, which are FDA-approved for treating diabetes and obesity, have been shown to reduce voluntary drug taking and seeking in preclinical models of cocaine used disorder. However, the exact neural circuits and cell types that mediate the suppressive effects of GLP-1R agonists on cocaine-seeking behavior are mostly unknown.
Opioid users can develop chronic inflammation and heightened pain sensitivity. These side effects might stem from the body’s own immune system, which can make antibodies against the drugs. The researchers will present their results at the American Chemical Society Fall 2020 Virtual Meeting & Expo.